## The Unexpected Protective Role of Thrombosis in Sepsis-Induced

### Inflammatory Lung Injury Via Endothelial Alox15

Authors: Colin E. Evans<sup>1, 2, 3</sup>, Xianming Zhang<sup>1, 2, 3</sup>, Narsa Machireddy<sup>1, 2, 3</sup>, and You-Yang

Zhao<sup>1, 2, 3, 4, 5, 6\*</sup>

**Affiliations:** 1. Program for Lung and Vascular Biology; and 2. Section for Injury Repair and Regeneration Research, Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA. 3. Department of Pediatrics, Division of Critical Care, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 4. Department of Pharmacology; 5. Department of Medicine, Division of Pulmonary and Critical Care Medicine; 6. Feinberg Cardiovascular and Renal Research Institute; Northwestern University Feinberg School of Medicine; Northwestern University Feinberg School of Institute; Northwestern University Feinberg School of Medicine; Northwestern University Feinberg School of Medicine, Northwestern University Feinberg School of Medicine; Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.

\*Correspondence: youyang.zhao@northwestern.edu.

## 1 Abstract:

Background. Patients with sepsis-induced acute lung injury (ALI)/acute respiratory distress
syndrome (ARDS) commonly suffer from severe pulmonary thrombosis, but clinical trials of anticoagulant therapies in sepsis and ARDS patients have failed. ARDS patients with
thrombocytopenia also exhibit increased mortality, and widespread pulmonary thrombosis is often
seen in coronavirus disease 2019 (COVID-19) ARDS patients.

Methods. Employing different amounts of microbeads to induce various levels of pulmonary thrombosis. Acute lung injury was induced by either lipopolysaccharide i.p. or cecal ligation and puncture. Endothelial cell (EC)-targeted nanoparticle coupled with CDH5 promoter was employed to delivery plasmid DNA expressing the CRISPR/Cas9 system for EC-specific gene knockout or expressing Alox15 for EC-specific overexpression. Additionally, thrombocytopenia was induced by genetic depletion of platelets using *DTR*<sup>*Pf4Cre*</sup> mice by breeding *Pf4*Cre mice into the genetic background of *DTR* mice.

14 **Results.** We show that while severe pulmonary thrombosis or thrombocytopenia augments sepsis-induced ALI, the induction of mild pulmonary thrombosis conversely reduces endothelial 15 cell (EC) apoptosis, ALI, and mortality via sustained expression of endothelial arachidonate 15-16 17 lipoxygenase (Alox15). Endothelial Alox15 knockout via EC-targeted nanoparticle delivery of 18 CRISPR/Cas9 plasmid DNA in adult mice abolished the protective impact of mild lung thrombosis. Conversely, overexpression of endothelial Alox15 inhibited the increases in ALI caused by severe 19 pulmonary thrombosis. The clinical relevance of the findings was validated by the observation of 20 reduced ALOX15-expressing ECs in lung autopsy samples of ARDS patients. Additionally, 21 22 restoration of pulmonary thrombosis in thrombocytopenic mice also normalized endotoxemia-23 induced ALI.

- 24 Conclusion. We have demonstrated that moderate levels of thrombosis protect against sepsis-
- 25 induced inflammatory lung injury via endothelial Alox15. Overexpression of Alox5 inhibits severe
- 26 pulmonary thrombosis-induced increase of ALI. Thus, activation of ALOX15 signaling represents
- a promising therapeutic strategy for treatment of ARDS, especially in sub-populations of patients
- 28 with thrombocytopenia and/or severe pulmonary thrombosis.
- 29 Key Words: Acute lung injury, acute respiratory distress syndrome, ALOX15, endothelial cells,
- 30 inflammation, sepsis, thrombosis

## 31 Introduction

Sepsis is an infection-induced uncontrolled inflammatory response that often results in 32 acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) <sup>1-3</sup>. Despite improvements in 33 supportive care for patients with ALI/ARDS, including mechanical ventilation and antibiotic 34 35 therapy, there is currently no effective treatment for ALI/ARDS, and mortality rates for patients with ARDS are as high as 40% <sup>1-3</sup>. The lack of effective treatments for ALI/ARDS is likely due to 36 an incomplete understanding of the mechanisms that control the pathogenesis of ALI/ARDS. 37 Given that anti-inflammatory therapies have been unsuccessful in the treatment of ARDS <sup>4, 5</sup>, it is 38 39 likely that ALI/ARDS is regulated by factors other than inflammation alone. For instance, ALI/ARDS is characterized by increased levels of thrombosis <sup>1, 6, 7</sup>. Widespread pulmonary 40 thrombosis is often seen in coronavirus disease 2019 (COVID-19) ARDS patients 8-11. 41 42 Thrombocytopenia is also associated with increased mortality in patients with sepsis and ARDS <sup>12-14</sup>. Increased microvascular thrombosis and thrombocytopenia are hallmarks of disseminated 43 intravascular coagulation (DIC), which is common in sepsis and ARDS patients <sup>15-17</sup>. However, 44 the impact of thrombosis and thrombocytopenia on ALI is ambiguous <sup>18</sup>. For example, pulmonary 45 thrombosis impedes the delivery of oxygen and nutrients from blood to the lung, while 46 47 simultaneously acting as a barrier to prevent bacterial exchange <sup>19, 20</sup>. Crucially, comprehensive investigations of the impact of varying levels of pulmonary thrombosis and of the underlying 48 49 mechanisms on ALI/ARDS are absent to date.

Another characteristic of ALI/ARDS is increased lung endothelial cell (EC) apoptosis and injury <sup>21-23</sup>. A viable lung EC monolayer is essential for the maintenance of vascular homeostasis <sup>24-26</sup>, while reduced lung EC survival leads to impaired endothelial barrier function, including increased capillary permeability and pulmonary fluid imbalance <sup>2, 23, 25, 26</sup>. Pulmonary EC apoptosis has been shown in experimental models of sepsis and ALI/ARDS <sup>27-31</sup> and in ARDS clinical samples <sup>21</sup>. Despite these observations, and the possibility that improving lung EC survival could

be a useful strategy to combat ALI/ARDS <sup>32, 33</sup>, the effect of differing severities of lung thrombosis
 on pulmonary EC survival in ALI/ARDS is also unknown.

Given that anti-coagulants have failed in clinical trials of sepsis/ARDS <sup>34-37</sup> and that 58 experimental thrombosis stimulates an angiogenic response <sup>38, 39</sup>, we hypothesized that mild 59 60 levels of pulmonary thrombosis could protect against sepsis-induced ALI. In this study, we aimed 61 to determine the impact of varying levels of pulmonary thrombosis on sepsis-induced ALI, and to delineate the underlying molecular mechanisms. We found that the induction of severe levels of 62 63 pulmonary thrombosis augmented EC apoptosis and ALI in sepsis mice, while a mild level of 64 pulmonary thrombosis conversely protected against ALI and mortality via endothelial arachidonate 15-lipoxygenase (Alox15). EC-targeted overexpression of Alox15 inhibited the 65 66 increases in ALI caused by severe pulmonary thrombosis. Restoration of mild levels of pulmonary 67 thrombosis inhibited thrombocytopenia-induced increases in ALI and mortality in platelet-depleted 68 sepsis mice. The clinical relevance of the study was supported by our observation that there are markedly reduced ALOX15-expressing ECs in the pulmonary vasculature of ARDS lungs 69 compared with normal lungs. 70

## 72 Results

## 73 *Mild pulmonary thrombosis attenuates, whereas severe thrombosis augments,* 74 *inflammatory lung injury in endotoxemia mice*

Pulmonary thrombosis may have protective or detrimental effects on ALI, so we first 75 76 investigated the impact of different levels of pulmonary thrombosis on ALI. Wild type (WT) mice 77 received various amounts of polystyrene microbeads (MBs) (i.v.) or vehicle to quantitatively induce pulmonary thrombosis <sup>39</sup>. At 24hrs later, mice received i.p. lipopolysaccharide (LPS) to 78 induce endotoxemia <sup>29, 40</sup>, and lung injury was assessed at 36hrs post-LPS (i.e., at the time of 79 80 peak injury). A dose of 1,000 MBs/mouse led to the greatest reduction in lung vascular permeability (as measured by Evans blue-conjugated albumin [EBA] flux) and neutrophil 81 sequestration (indicated by myeloperoxidase [MPO] activity) <sup>29, 40</sup> versus MB-free endotoxic mice 82 (Fig. 1, A and B). Conversely, increasing the MB number resulted in dose-dependent increases 83 in lung vascular permeability, with 200.000 MBs/mouse resulting in highest levels of lung vascular 84 permeability versus vehicle-treated endotoxic controls (Fig. 1A). MPO activity was also markedly 85 increased in mice who received 200,000 MBs compared to MB-free endotoxic controls (Fig. 1B). 86 The protective dose of 1,000 MBs/mouse (referred to herein as innocuous) also reduced 87 88 apoptosis in pulmonary ECs compared with that found in MB-free endotoxic mice, while the detrimental dose of 200,000 MBs/mouse (referred to herein as severe) worsened pulmonary EC 89 90 apoptosis (Fig. 1, C to E). In confirmatory studies, we verified that the innocuous MB dose did 91 indeed increase the levels of lung thrombosis above those found in vehicle-treated endotoxic 92 controls, and that this level was further enhanced by the severe dose of MBs (Fig. 1, F to H).

We next extended our studies of the protective effects of the innocuous level of pulmonary
thrombosis on lung injury. Consistent with reduced pulmonary vascular permeability (Fig. 2A),
1,000 MBs treatment decreased lung edema assessed by lung wet/dry weight ratio in sepsischallenged but not basal mice (Fig. 2B). Assessment of lung histology also revealed a marked

97 reduction in alveolar edema and septal thickening in 1,000 MBs-treated endotoxemic mice
98 compared to vehicle-treated endotoxemic mice (Fig. 2, C to E).

To determine whether the innocuous dose of MBs could inhibit inflammatory lung injury 99 100 when given after sepsis challenge, the 1,000 MBs were administered to WT mice at 2 or 8hrs 101 after LPS challenge. As shown in Fig. 2, F and G, the protective impact of this innocuous level of 102 pulmonary thrombosis on inflammatory lung injury, evidenced by marked reductions of lung EBA flux and MPO activity at 36hrs post-LPS, was maintained even when the MBs were given at 8hrs 103 post-LPS challenge. Furthermore, treatment with 1,000 MBs promoted survival in mice 104 105 challenged with a lethal dose of LPS, regardless of whether the MBs were administered before or after sepsis challenge (Fig. 2H). Together, these data demonstrate that while severe 106 107 pulmonary thrombosis enhance inflammatory lung injury, mild pulmonary thrombosis protects 108 against inflammatory lung injury induced by endotoxemia.

109

## 110 Molecular profiling of genes involved in the protective effects of mild lung thrombosis

To elucidate molecular pathways through which mild pulmonary thrombosis protects 111 against inflammatory lung injury, we next performed RNA sequencing analysis. In these studies, 112 113 whole lung samples were analyzed from sepsis-free WT mice (basal group) and from LPS-treated WT mice without MBs (vehicle group) or with mild (1,000 MBs/mouse) or severe (200,000 114 MBs/mouse) pulmonary thrombosis. Lung samples were collected for analysis at 24hrs post-LPS. 115 116 Of the 15,531 genes detected by RNA sequencing analysis, we selected the genes whose 117 expression levels varied from one group to another by  $\geq$  2-fold, yielding a list of 82 genes. Of 118 these 82 genes, 12 are known to regulate cell survival (Fig. 3A). Of these 12 genes, the expression patterns of 9 genes were validated in whole lung samples by gRT-PCR analysis (Fig. 119 **3B** and **Fig. S1**). The expression of 6 of these genes was increased in lung samples of LPS mice 120 121 treated with 1,000 MBs compared with mice receiving LPS alone, but not in LPS mice treated with

200,000 MBs (**Fig. 3B**). Quantitative (Q)RT-PCR analysis of isolated cells further showed that these 6 genes were increased in either pulmonary non-ECs (i.e., Ghrl and Ms4a1), pulmonary ECs (i.e., Alox15 and Cd22), or both pulmonary non-ECs and ECs (i.e., Pla2g2d and Serpinb2) of 1,000 MBs-treated mice (**Fig. 3, C** and **D**). These data suggested that mild pulmonary thrombosis could protect against inflammatory lung injury via attenuation of sepsis-induced decreases of the expression of factors that regulate cell survival.

128

## 129 Endothelial Alox15 mediates the protective effects of mild lung thrombosis

130 Given that mild lung thrombosis resulted in increased expression of Alox15 and Cd22 in pulmonary ECs but not non-ECs, we next determined whether either of these factors was 131 132 responsible for the protective effects of mild thrombosis. We employed nanoparticle-targeted 133 delivery of an all-in-one CRISPR plasmid DNA expressing Cas9 under control of the human CDH5 134 promoter and guide RNA by the U6 promoter, to delete either of these 2 genes selectively in ECs of adult mice (Fig. 4A). Consistent with a previous study, which demonstrated ~80% decreases 135 136 in protein expression <sup>41</sup>, gPCR analysis demonstrated an approximately 40% genome editing 137 efficiency in the Alox15 or Cd22 locus in ECs but not non-ECs of the respective CRISPR plasmidtransduced mice (Fig. S2, A and B). We confirmed an 80% decrease of EC-specific Alox15 at 138 139 the protein level (**Fig. 4B**). Seven days after nanoparticle:CRISPR plasmid DNA administration, 140 the mice receiving plasmid DNA expressing the scrambled guide RNA (WT group) or genomeedited mice were administered either vehicle or 1,000 MBs followed by LPS challenge at 24hrs 141 142 after vehicle or MBs, and lungs were assessed at 36hrs post-LPS (Fig. 4A). As shown in Fig. 4C, CRISPR-mediated disruption of endothelial Alox15 but not Cd22 reversed the 1,000 MBs-induced 143 144 decrease in pulmonary EBA flux. Consistently, lung MPO activity in endothelial Alox15- but not 145 Cd22-genome-edited mice treated with 1,000 MBs was markedly elevated compared to 1,000 MBs-treated WT mice (Fig. 4D). These data provide clear evidence that mild lung thrombosis 146

protects against inflammatory lung injury via endothelial Alox15 but not Cd22. Furthermore, we observed endothelial-specific disruption of *Alox15* restored histological lung injury in 1,000 MBs-treated mice to levels comparable with vehicle-treated WT mice, in contrast to 1,000 MBs-treated WT mice (**Fig. 4, E** and **F**). Next, we showed that the inhibition of endothelial apoptosis by 1,000 MBs in WT mice was also reversed in *Alox15* genome-edited mice (**Fig. 4, G** to **I**). These data together demonstrate that mild lung thrombosis reduces inflammatory lung injury via endothelial Alox15.

154

# Overexpression of Alox15 in ECs inhibits the detrimental effect of severe lung thrombosis in septic mice

157 Given that severe pulmonary thrombosis failed to reverse the sepsis-induced 158 downregulation of Alox15, we next determined whether restoration of expression of Alox15 in ECs 159 could reverse the deleterious impact of severe lung thrombosis on ALI. Twenty hours after administration of the mixture of nanoparticles: plasmid DNA expressing Alox15 under the control 160 of CDH5 promoter or empty vector, the mice were challenged with LPS, then treated with vehicle 161 or 200,000 MBs/mouse at 2hrs after LPS. Lungs were assessed at 36hrs post-LPS (Fig. 5A). 162 163 QRT-PCR analysis demonstrated a marked increase in Alox15 mRNA expression selectively in lung ECs of Alox15 plasmid-transduced mice compared with vector mice (Fig. S3), which was 164 confirmed at the protein level (Fig. 5B). The 200,000 MBs-induced increase in pulmonary 165 166 vascular permeability was inhibited by EC-specific Alox15 overexpression in Alox15 plasmid-167 transduced mice (Fig. 5C). Histological increases in lung edema and septal thickening caused by 168 200,000 MBs/mouse were also abolished by EC-specific Alox15 overexpression in Alox15 plasmid-transduced mice with severe lung thrombosis (Fig. 5, D and E). Similarly, the severe lung 169 thrombosis-induced increase of lung EC apoptosis was also inhibited by EC-specific Alox15 170 171 overexpression (Fig. 5, F to H). These data suggest that increases in ALI resulting from severe

172 lung thrombosis can be reversed by an EC-targeted gene therapy approach to restore endothelial173 Alox15 expression.

174

## 175 Restoration of mild levels of pulmonary thrombosis attenuate thrombocytopenic ALI

176 Given that thrombocytopenia is associated with decreased survival in sepsis patients <sup>12, 13</sup> 177 and with increased risk of developing ARDS, as well as decreased survival in ARDS patients <sup>14</sup>. we next wished to determine whether thrombocytopenia-induced increases in ALI could be 178 179 inhibited through restoration of an innocuous level of lung thrombosis. To generate thrombocytopenic mice, we used a genetic mouse model of platelet depletion in which 180 thrombocytopenia is induced by diphtheria toxin (DT) treatment of mice expressing the DT 181 receptor (DTR) in platelets and megakaryocytes controlled by *Pf4*Cre<sup>42</sup>. We first showed that 182 circulating levels of platelets are reduced in this *DTR*<sup>Pf4Cre</sup> model (i.e., PF4 group) to <10% of 183 184 levels found in DTR<sup>Pi4-</sup> controls (i.e., WT group); this reduction occurred by day 2 after DT treatment and remained suppressed to this extent for at least 3days (Fig. S4A) without altering 185 leukocyte numbers (Fig. S4, B to G). In subsequent studies of thrombocytopenic mice, LPS was 186 administered at the start of this period of platelet depletion and lungs were assessed at the time 187 188 point of peak injury (i.e., 36hrs post-LPS). While thrombocytopenia did not alter basal levels of lung thrombosis in LPS-free mice, sepsis challenge gave rise to increases in lung thrombosis in 189 WT mice, and these increases were attenuated by thrombocytopenia (Fig. S5. A to C). 190 191 Concomitantly, in LPS-treated mice, thrombocytopenia resulted in exacerbated levels of 192 inflammatory lung injury, evidenced by increased lung EBA flux (Fig. S6A) and MPO activity (Fig. 193 **S6B**), as well as histological evidence of increased lung edema and alveolar septum thickening (Fig. S6, C to E). These data demonstrate that thrombocytopenia impairs sepsis-induced lung 194 thrombosis and increases inflammatory lung injury. 195

197 To determine whether thrombocytopenia-induced increases in inflammatory lung injury 198 following sepsis challenge could be rescued by restoration of an innocuous level of lung 199 thrombosis, we next administered i.v. MBs at 24hrs prior to LPS challenge in thrombocytopenic 200 mice (Fig. 6A). Starting with the protective dose of 1,000 MBs/mouse identified above in WT mice, 201 we found that increasing doses of i.v. MBs gave rise to increasing levels of lung thrombosis in 202 thrombocytopenic sepsis-challenged mice, and that these increases occurred in a dosedependent manner (Fig. 6, B and C). The dose of MBs that restored lung thrombosis in PF4 mice 203 204 to the levels found in sepsis-challenged WT mice was 2,000 MBs/mouse (Fig. 6, B and C). 205 Importantly, 2,000 MBs/mouse did not alter the basal levels of lung EBA flux and MPO activity in either platelet-replete (i.e., WT) or thrombocytopenic mice (data not shown). We then assessed 206 207 inflammatory lung injury in LPS-treated mice and found that this dose of 2,000 MBs/mouse 208 completely abolished the thrombocytopenia-induced increases in inflammatory lung injury as 209 assessed by histology (Fig. 6, D to F), EBA flux (Fig. 6G), and MPO activity (Fig. 6H). A dose of 2,000 MBs/mouse elicited the optimal protective effect compared to 1,000 MBs/mouse, 3,000 210 211 MBs/mouse, and 5,000 MBs/mouse (Fig. 6, G and H). However, a high dose of 100,000 MBs/mouse, resulting in excessive thrombosis (Fig. 6C), had no protective effects in PF4 212 213 thrombocytopenic mice and returned the levels of sepsis-induced inflammatory lung injury to that found in MB-free thrombocytopenic mice (Fig. 6, D to F). 214

Next, we observed that the beneficial dose of 2,000 MBs/mouse inhibited thrombocytopenia-induced increases in lung EBA flux and MPO activity, even when the MBs were given at 2hrs after LPS (**Fig. 6**, **I** and **J**). Consistent with these findings, thrombocytopenia reduced survival in PF4 mice challenged with lethal doses of LPS, but survival was improved by the restoration of an innocuous level of lung thrombosis either before or after sepsis challenge (**Fig. 6K**). These data suggest that thrombocytopenia worsens ALI at least in part through impaired

lung thrombosis, and that restoration of an innocuous level of lung thrombosis can protect against
 thrombocytopenia-induced ALI.

223

## 224 Mild pulmonary thrombosis is also protective against inflammatory lung injury induced by

#### 225 polymicrobial sepsis via endothelial Alox15

226 We next determined the effects of various levels of pulmonary thrombosis on inflammatory lung injury in a mouse model of polymicrobial sepsis induced by cecal ligation and puncture (CLP). 227 228 Similar to endotoxemia mice, sepsis-induced increases of EBA flux, MPO activity, endothelial 229 apoptosis, and histological lung injury were reduced in mice treated with 1,000 MBs/mouse 230 whereas exaggerated in mice treated with 200,000 MBs/mouse (Fig. 7, A and B, Fig. S7, and 231 Fig. S8). To determine if the protective effects of mild pulmonary thrombosis are also mediated 232 by endothelial Alox 15, we employed EC-targeted nanoparticle delivery of CRISPR/Cas9 plasmid 233 to selectively knockout Alox15 in ECs in adult mice. The mice were then treated with 1,000 234 MBs/mouse followed by CLP challenge. As shown in Fig. 7, C-I, 1,000 MB-induced decreases in EBA flux, MPO activity, endothelial apoptosis, and histological lung injury in WT mice were 235 abrogated in endothelial Alox15 knockout mice. 236

237

## 238 ALOX15<sup>+</sup> ECs are diminished in lung samples of ARDS patients

To explore the clinical relevance of our findings, we assessed endothelial *ALOX15* expression in human lungs. *In situ* RNA hybridization (RNAscope) assays of lung sections taken postmortem from 6 ARDS patients (2 males, 4 females, 34-67 years old) and 6 unused normal donor lungs (4 males, 2 females, 43-56 years old) revealed that the proportion of lung ECs that were *ALOX15*<sup>+</sup> was markedly reduced in ARDS patients compared with normal controls (**Fig. 8**, **A** and **B**). These data suggest that ALOX15 in human lung ECs is also protective against inflammatory lung injury.

## 246 **Discussion**

247 Our studies demonstrate that while a diminished or severely increased level of lung thrombosis promotes sepsis-induced ALI, a mildlevel of lung thrombosis induces an EC survival 248 249 response and protects against ALI (Fig. 8C). Restoration of a mild level of lung thrombosis in 250 platelet-depleted mice inhibits the thrombocytopenia-induced increases in lung injury and 251 promotes survival. Furthermore, we show in 2 discrete mouse models of sepsis-induced ALI, that the protective effects elicited by mild lung thrombosis are mediated by endothelial Alox15. Loss 252 253 of endothelial Alox15 abolished the protective effects, while overexpression of endothelial Alox15 254 protected against severe thrombosis-induced increases in EC death and lung injury. In ARDS patients, ALOX15<sup>+</sup> ECs of the pulmonary vasculature were markedly reduced. Together, these 255 256 studies provide a comprehensive understanding of the role of varying levels of lung thrombosis in 257 the pathogenesis of inflammatory lung injury. Activation of ALOX15 signaling (e.g., via EC-258 targeted nanoparticle delivery of the ALOX15 gene) is a potential effective therapeutic strategy for the treatment of ALI/ARDS caused by sepsis, particularly in patient sub-populations with 259 260 thrombocytopenia or severe pulmonary thrombosis.

In our studies, increasing doses of i.v. MBs were used to quantitatively induce lung 261 262 thrombosis in a stepwise manner. The MB size used in the current study (15 µm diameter) was 263 selected to ensure seeding into the lung microvasculature <sup>39</sup>. The same kind of MBs were also used to induce lung thrombosis in a previous study of lung tumorigenesis in WT mice and 264 triggered a pro-angiogenic response in the pulmonary vasculature <sup>39</sup>. We showed herein that the 265 266 innocuous level of lung thrombosis did not induce lung injury or inflammation in LPS-free (basal) 267 mice. It should be noted here that MBs have been previously used to induce chronic thromboembolic pulmonary hypertension (CTEPH); the 15 µm MBs used in our study, however, 268 are almost 6 times smaller than the MBs used to induce CTEPH in rats (85µm diameter) <sup>43</sup> and 269 20 times smaller than the MBs in dogs (100-300µm diameter)<sup>44</sup>. Furthermore, in a previous rodent 270

study of CTEPH, a one-off dose of 388,000 MBs/rat (85µm diameter) failed to induce a hypertensive response at 3 or 6wks after administration <sup>43</sup>, while repetitive administration of even larger MBs (100-300µm diameter) every 3-4 days takes >100days and >25,000 MBs/animal to induce a hypertensive response in dogs <sup>44</sup>. Although we did not assess pulmonary hypertension in the current study, the one-off doses of 1,000 or 2,000 MBs/mouse did not cause any discernable behavioral or respiratory changes or unexpected deaths in this study.

It has been suggested that severe levels of lung thrombosis could worsen ALI through 277 ischemia-induced cell death <sup>18</sup>. Our study shows that a dose of 200,000 MBs/mouse does indeed 278 279 increase EC apoptosis and enhance ALI. Conversely, mild lung thrombosis induced by 1,000 MBs/mouse protected against ALI in septic WT mice. It has also been suggested that thrombosis 280 281 could protect against ALI by preventing bacterial transport between the lung and blood, by 282 providing a binding site for pro-survival factors and cytokines, and by blocking leaky endothelial 283 junctions <sup>18, 45</sup>. Here we show that mild lung thrombosis protects against lung EC apoptosis and 284 ALI and promotes mouse survival via endothelial Alox15. Alox15 is an enzyme producing 12- and 15-hydroxyeicosatetraenoic acid from arachidonic acid. In previous studies <sup>46-48</sup>, allergen-induced 285 airway inflammation was diminished in global Alox15 knockout mice, while global Alox15 286 287 deficiency increased inflammation and necroptosis in a murine dermatitis model, and Alox15overexpressing transgenic rabbits were protected against periodontitis. In experimental models 288 of murine ALI, global Alox15 deletion or systemic inhibition has been previously shown to 289 290 decrease ALI following aerosolized LPS inhalation or intratracheal hydrochloric acid instillation, 291 which is largely mediated by hematopoietic Alox15, but global Alox15 deletion instead increased ALI following A. fumigatus infection. The apparent incongruence between reported findings could 292 293 be due to differences in experimental models and the use of global gene targeting methods, as well as disparities resulting from pro-versus anti-inflammatory effects of Alox15 and its enzymatic 294 295 products <sup>49</sup>. Nevertheless, we found that *Alox15* expression in total lung and in lung ECs was

296 downregulated following LPS challenge and that the innocuous level of lung thrombosis could 297 attenuate sepsis downregulation of endothelial Alox15 expression. Nanoparticle delivery of the CRISPR system-mediated disruption of endothelial Alox15 inhibited the protective effects of the 298 299 innocuous level of lung thrombosis and nanoparticle-targeted endothelial delivery of the Alox15 300 gene inhibited the severe thrombosis-induced increases in EC death and ALI in septic adult WT 301 mice. These EC-targeted gene therapy-like approaches avoided the potential cofounding effects of genetic compensation in transgenic/knockout mice as used in the aforementioned studies and 302 303 also modulate Alox15 expression only in ECs. Our findings together provide strong support for a 304 pro-survival role of endothelial Alox15 in lung ECs during inflammatory lung injury induced by 305 sepsis.

306 Finally, we employed a genetic mouse model of thrombocytopenia to show that platelet 307 depletion diminishes sepsis-induced lung thrombosis and increases inflammatory lung injury and 308 mortality in mice, and that the restoration of innocuous lung thrombosis protects against sepsis-309 induced inflammatory lung injury in the setting of thrombocytopenia. The inducible genetic model of thrombocytopenia enabled us to attenuate platelet levels and lung thrombosis without platelet-310 depleting antibodies or anti-coagulants, which also influence inflammation. By combining genetic 311 312 thrombocytopenia with MB-induced lung thrombosis, we were able to diminish then restore lung 313 thrombosis in a quantitative and stepwise manner in platelet-depleted mice; this finding was not 314 entirely surprising, given that thrombi still form even when platelet numbers are reduced. It was 315 also unsurprising that a relatively higher dose of MBs (i.e., 2,000 MBs/mouse) was required to 316 induce the optimal protective level of lung thrombosis in thrombocytopenic compared with WT 317 mice (i.e., 1,000 MBs/mouse), given the established contribution of platelets to thrombus formation. These studies help us understand the role of varying levels of thrombosis in the 318 pathogenesis of ALI and the failure of anti-coagulant therapies in clinical trials of sepsis/ARDS 319 patients 34-37. 320

321 In summary, our studies provide unequivocal evidence that: (i) mild lung thrombosis 322 inhibits sepsis-induced ALI via endothelial Alox15; (ii) severe lung thrombosis increases sepsis-323 induced ALI, which can be attenuated by EC overexpression of Alox15; (iii) normalization of lung 324 thrombosis inhibits thrombocytopenia-induced increases in ALI; and (iv) ARDS patients have 325 reduced levels of ALOX15<sup>+</sup> lung ECs, which validates the clinical relevance of our findings. Our surprising finding that mild lung thrombosis is protective may explain the lack of efficacy of anti-326 327 coagulant therapies seen in clinical trials of sepsis/ARDS patients. Thus, tuning of lung 328 thrombosis to a protective level, or activation of ALOX15 signaling (e.g., through EC-targeted 329 nanoparticle delivery of endothelial ALOX15 gene), represent promising therapeutic strategies against ALI/ARDS caused by sepsis. 330

## 332 Materials and Methods

Mice. Animal care and study protocols were reviewed and approved by the Northwestern 333 University Feinberg School of Medicine Institutional Animal Care and Use Committee. Male and 334 female C57BL/6J mice (aged 12-16wks) were used throughout the studies. For studies of 335 336 thrombocytopenia (i.e., platelet depletion), Pf4Cre mice (The Jackson Laboratories, USA) were bred with DTR mice (The Jackson Laboratories, USA) to generate DTR<sup>Pf4Cre</sup> mice (referred to 337 herein as PF4 mice). In these studies, littermate *Pf4*Cre<sup>-</sup> mice (*DTR*<sup>*Pf4-*</sup>) served as WT controls 338 (referred to herein as WT mice). To induce genetic thrombocytopenia, DTR<sup>Pf4Cre</sup> or DTR<sup>Pf4-</sup> mice 339 received diphtheria toxin (DT) (20ng/g/day, i.p., Sigma-Aldrich, USA) for 3days. Blood was 340 collected by cardiac puncture into EDTA-coated tubes and complete blood cell counts were 341 342 performed using an automatic hematology analyzer (Advia 120, Siemens, USA).

343

344 Nanoparticle-targeted EC-specific gene knockout and overexpression in adult mice. EC-345 specific disruption of Alox15, or Cd22 expression in adult mice were achieved using nanoparticlemediated genome editing as described previously<sup>41</sup>. In short, EndoNP1 nanoparticles (Mountview 346 Therapeutics LLC, USA) were incubated at room temperature for 10mins with the all-in-one 347 348 plasmid DNA expressing Cas9 under the control of the EC-specific CDH5 promoter and gene-349 specific guide RNA driven by the U6 promoter following the manufacturer's instructions, then administered intravenously (retro-orbitally) to C57BL/6J WT adult mice (40µg plasmid 350 DNA/mouse). Seven days later, the genome-edited mice were used for studies. Mice treated with 351 nanoparticles plus plasmid DNA expressing scrambled RNA served as wild type (WT) controls. 352

EC-specific *Alox15* overexpression in adult mice was also achieved using nanoparticlemediated gene transduction. Briefly, EndoNP1 nanoparticles were mixed with plasmid DNA expressing mouse *Alox15* driven by *CDH5* promoter or empty vector (control) for 10mins at room

temperature and then administered to C57BL/6J WT adult mice retro-orbitally (20µg of plasmid
 DNA/mouse). Mice were sacrificed at 62hrs post-administration.

358

Mouse model of endotoxemia. To induce endotoxemia, mice received LPS (Santa Cruz Biotechnology, Inc, USA) at a dose of 3mg/kg body weight for sub-lethal injury studies, and 4-6mg/kg for survival studies, i.p. as previously described <sup>29, 40</sup>.

362

363 Mouse model of polymicrobial sepsis. To induce polymicrobial sepsis, mice underwent CLP as previously described <sup>40</sup>. Briefly, mice were anesthetized with inhaled isofluorane (2.5% mixed 364 with room air). When the mouse failed to respond to paw pinch, buprenex (0.1 mg/kg) was 365 366 administered subcutaneously prior to proper sterilization of the skin with providone iodine, and then a midline abdominal incision was made. The cecum was exposed and ligated with a 3-0 367 silk tie 1 cm from the tip and the cecal wall was perforated with a 20-gauge needle. Control 368 369 (sham) mice underwent anesthesia, laparotomy, and wound closure but no cecal ligation and 370 puncture. Immediately following the procedure, 500ul of warmed normal saline was 371 administered subcutaneously. Within 5min following surgery, the mice were able to wake from anesthesia. The mice received a second dose of buprenex at 6-8h post-surgery 372 373 subcutaneously. 374

Mouse model of pulmonary thrombosis. To induce lung thrombosis, mice received polystyrene
 microbeads (MBs, 15µm diameter, Invitrogen, USA) i.v. as previously described <sup>39</sup>.

377

378 Lung histology. Formalin-fixed paraffin-embedded lung sections (5µm) were stained with 379 hematoxylin and eosin (H&E) or martius scarlet blue (MSB) as previously described <sup>39, 50</sup>. Imaging was performed using a brightfield microscope (Zeiss Axio, USA) with mounted camera and 380 integrated imaging software (ZEN 2.6, USA). Incidence of alveolar edema and septal thickening 381 382 were counted in a blinded manner in H&E-stained lung sections. Incidence of thrombosis and 383 fibrin area were assessed in a blinded manner in MSB-stained lung sections as previously described <sup>39,50</sup>. For each mouse, the incidence of edema, septal thickening, and microvascular 384 385 thrombosis was counted in 10 randomly selected 20x fields. Percentage fibrin coverage was also 386 assessed in 10 randomly selected 20x fields using image analysis software (ImageJ, NIH, USA). 387 Data are expressed as an average per field.

388

Lung vascular permeability measurement. Lung vascular permeability was assessed by measurement of lung EBA flux as previously described <sup>40</sup>. Briefly, EBA (20mg/kg) was injected retro-orbitally 30mins before lungs were perfused with PBS free of blood. Lungs were then collected, blotted dry, weighed, and homogenized in 0.5ml PBS and then incubated with 1ml formamide at 60°C for 18hrs. Lung homogenates were centrifuged at 21,000g for 10mins. Optical density of the supernatant was determined at 620nm and 740nm.

395

**Myeloperoxidase (MPO) activity assay**. Lung MPO activity was assessed as previously described <sup>29, 40</sup>. Briefly, PBS-perfused lungs were homogenized in 0.5ml of 50mM phosphate buffer. Homogenates were centrifuged at 21,000g for 15mins at 4°C. Thereafter, the pellets were resuspended in phosphate buffer with 0.5% hexadecyl trimethylammonium bromide and subjected to a freeze-thaw cycle. Subsequently, the homogenates were centrifuged at 21,000g for 15mins at 4°C. Following addition of 34µl of sample to 10µl of O-dianisidine dihydrochloride

402 (16.7mg/ml) and  $50\mu$ l of H<sub>2</sub>O<sub>2</sub> (0.015% v/v) in 1ml of phosphate buffer, absorbance was measured 403 at 460nm every 20secs for 3mins.

404

TUNEL staining. Lung apoptosis was assessed by quantification of TUNEL-positive cells in lung 405 cryo-sections (5µm) using an In Situ Cell Death Detection Kit (Roche, USA) according to 406 manufacturer's instructions as previously described <sup>29</sup>. Lung ECs were co-stained with anti-CD31 407 408 antibody (1:40 dilution, Abcam, USA) and anti-vWF antibody (1:250 dilution, Sigma, USA) for 18hrs at 4°C. Sections were incubated with Texas Red-conjugated secondary antibody (1:300 409 410 dilution, Invitrogen, USA) for 1hr at room temperature. Nuclei were counterstained with DAPI. 411 Imaging was performed using a confocal microscope (Zeiss LSM 880, USA) with mounted camera 412 and integrated imaging software (ZEN 2.6, USA). For each mouse, the number of apoptotic ECs 413 (CD31/vWF<sup>+</sup> TUNEL<sup>+</sup>) and the number of apoptotic non-ECs (CD31/vWF<sup>-</sup> TUNEL<sup>+</sup>) were counted in a blinded manner in 10 randomly selected 25x fields. Data are expressed as an average 414 number per 1,000 nuclei. 415

416

EC isolation. CD31<sup>+</sup> ECs and CD31<sup>-</sup> non-EC fractions were isolated using magnetic-activated 417 cell sorting as previously described <sup>40</sup>. Briefly, PBS-perfused lungs were cut into small pieces and 418 incubated in 1mg/mL collagenase A (Roche, USA) for 1hr at 37°C in a shaking water bath 419 420 (200rpm). The lung samples were then dissociated into a single-cell preparation using the gentleMACS Dissociator (Miltenyi Biotec, USA) and filtered through a 40µm nylon cell strainer. 421 The single-cell preparation was then blocked with 20% fetal bovine serum for 30mins and 422 423 incubated with anti-CD31 antibody (Abcam, USA) for 30mins at room temperature, followed by 424 capture of CD31<sup>+</sup> ECs with magnetic anti-rat IgG-conjugated Dynabeads (Invitrogen, USA) for

30mins. EC specificity was confirmed by quantitative RT-PCR (qRT-PCR) demonstration of EC
marker enrichment versus whole lung samples.

427

**RNA sequencing analysis.** RNA expression was assessed in whole lung tissues by RNA sequencing analysis (Novogene, USA). Briefly, lung samples were collected after perfusion free of blood and homogenized with Trizol (Invitrogen, USA) for RNA isolation. Isolated RNA was further purified with RNeasy minikit (Qiagen, USA) with DNase I digestion to remove genomic DNA. Purified RNA was sent to Novogene (USA) for RNA sequencing analysis.

433

*Molecular analyses.* To validate RNA sequencing data, RNA was isolated as described above.
Following reverse transcription, qPCR analysis was performed using the ABI ViiATM 7 real-time
PCR system (Thermo Fisher Scientific) with SYBR Green master mix to quantify the expression
of gene of interest. Mouse cyclophilin (*Cypa*) was used as housekeeping gene for normalization.
Nucleotide sequences are given in Table S1.

For quantification of genome editing efficiency, we employed a qPCR method as described previously <sup>41</sup>. Isolated lung ECs and non-ECs were lysed in proteinase K solution overnight at 60°C and genomic DNA was purified by standard pheno:chloroform extraction. qPCR analysis of the wild-type genomic DNA without Indels was performed on genomic DNA samples using the ABI ViiATM 7 real-time PCR system (Thermo Fisher Scientific) with SYBR Green master mix. Nme1 genomic DNA amplification was used as normalization. Nucleotide sequences are given in **Table S1**.

446 Protein levels of Alox15 were measured in isolated lung ECs and non-ECs by enzyme447 linked immunosorbent assay according to manufacturer's instructions (Abbexa, USA). Protein

levels are expressed per mg soluble protein as measured by the Bradford Assay according tomanufacturer's instructions (Bio-Rad, USA).

450

Identification of potent guide RNA for in vivo study. Potent guide RNAs were identified for in 451 vivo studies as previously described <sup>41</sup>. Briefly, 4 guide RNAs for each gene were designed using 452 453 the Genscript guide RNA database and the correspondent DNA oligoes were subcloned to the CRISPR<sup>CAG</sup> plasmid DNA expressing antibiotic gene against puromycin. Hepa-1c1c7 cells 454 (ATCC, USA) were cultured in DMEM plus 10% FBS, 100U/ml penicillin, and 100µg/ml 455 456 streptomycin. At 50-70% cell density, the Hepa-1c1c7 cells in complete medium were transfected with the all-in-one CRISPR<sup>CAG</sup> plasmid DNA using EndoNP1 nanoparticles. The transfected cells 457 458 were then treated with puromycin (500ng/ml) for selection. The selected cells were then collected 459 for genomic DNA isolation by standard phenol:chloroform extraction. QPCR analysis was performed on genomic DNA samples using the ABI ViiATM 7 real-time PCR system (Thermo 460 461 Fisher Scientific) with SYBR Green master mix. Nme1 genomic DNA amplification was used as normalization. Nucleotide sequences are given in Table S1. 462

463

In situ RNA hybridization (RNAscope analysis). Formalin-fixed paraffin-embedded lung 464 sections from patients with ARDS or from normal control subjects (unused donor lungs) were 465 466 subjected to in situ RNA hybridization assay (RNAscope assay) for ALOX15 mRNA expression according to manufacturer's instructions (ACD Bio, USA). Lung ECs were co-immunostained with 467 anti-CD31 antibody (1:40 dilution, Abcam, USA) and anti-vWF antibody (1:250 dilution, Sigma, 468 469 USA) for 18hrs at 4°C. Sections were incubated with Texas Red-conjugated secondary antibody 470 (1:300 dilution, Invitrogen, USA) for 1hr at room temperature. Nuclei were counterstained with DAPI. Imaging was performed using a confocal microscope (Zeiss LSM 880, USA) with mounted 471

472 camera and integrated imaging software (ZEN 2.6, USA). For each individual, the number of
473 ALOX15<sup>+</sup> CD31/vWF<sup>+</sup> ECs were counted in a blinded manner in 15 randomly selected blood
474 vessels. Data are expressed as an average percentage of blood vessel ECs.

475

*Human lung samples*. Archived post-mortem human lung samples from ARDS patients were
obtained from the University of Illinois at Chicago Biorepository. Lung samples from unused donor
lungs from the Pulmonary Hypertension Breakthrough Initiative (PHBI) were used as controls.
The use of these archived samples was approved by the Ann & Robert H. Lurie Children's
Hospital of Chicago Institutional Review Board.

481

**Statistical analysis**. Statistical analyses were performed using Prism 9 (Graphpad Software, Inc., La Jolla, USA). Data normality was assessed using Shipiro-Wilk tests. Two group comparisons were assessed with unpaired 2-tailed t-tests. Multiple group comparisons were assessed using one- or two-way ANOVA with Bonferroni post-tests. Differences in survival were assessed using the log-rank (Mantel-Cox) test. P values of <0.05 were considered significant.

## 487 **References**

- Matthay MA, Zemans RL, Zimmerman GA, Arabi YM, Beitler JR, Mercat A, Herridge M,
   Randolph AG, Calfee CS. Acute respiratory distress syndrome. *Nat Rev Dis Primers*.
   2019;5:18
- 491 2. Lee WL, Slutsky AS. Sepsis and endothelial permeability. *N. Engl. J. Med.* 2010;363:689492 691
- 493 3. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson
  494 LD. Incidence and outcomes of acute lung injury. *N. Engl. J. Med.* 2005;353:1685-1693
- 495 4. Eichacker PQ, Parent C, Kalil A, Esposito C, Cui X, Banks SM, Gerstenberger EP, Fitz Y,

496 Danner RL, Natanson C. Risk and the efficacy of antiinflammatory agents: Retrospective

- 497 and confirmatory studies of sepsis. *Am J Respir Crit Care Med*. 2002;166:1197-1205
- 498 5. Opal SM, Fisher CJ, Jr., Dhainaut JF, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman

499 GJ, Levy H, Balk RA, Shelly MP, Pribble JP, LaBrecque JF, Lookabaugh J, Donovan H,

- 500 Dubin H, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M. 501 Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase iii, 502 randomized, double-blind, placebo-controlled, multicenter trial. The interleukin-1 receptor 503 antagonist sepsis investigator group. *Crit. Care Med.* 1997;25:1115-1124
- Ware LB, Matthay MA. The acute respiratory distress syndrome. *N. Engl. J. Med.* 2000;342:1334-1349
- 506 7. Matthay MA, Ware LB, Zimmerman GA. The acute respiratory distress syndrome. *J. Clin.* 507 *Invest.* 2012;122:2731-2740
- Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A,
   Werlein C, Stark H, Tzankov A, Li WW, Li VW, Mentzer SJ, Jonigk D. Pulmonary vascular
   endothelialitis, thrombosis, and angiogenesis in covid-19. *N. Engl. J. Med.* 2020;383:120 128
  - 24

- Matthay MA, Leligdowicz A, Liu KD. Biological mechanisms of covid-19 acute respiratory
  distress syndrome. *Am J Respir Crit Care Med.* 2020;202:1489-1491
- 10. D'Agnillo F, Walters KA, Xiao Y, Sheng ZM, Scherler K, Park J, Gygli S, Rosas LA, Sadtler
- 515 K, Kalish H, Blatti CA, 3rd, Zhu R, Gatzke L, Bushell C, Memoli MJ, O'Day SJ, Fischer TD,
- 516 Hammond TC, Lee RC, Cash JC, Powers ME, O'Keefe GE, Butnor KJ, Rapkiewicz AV,
- 517 Travis WD, Layne SP, Kash JC, Taubenberger JK. Lung epithelial and endothelial
- 518 damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal
- 519 covid-19. *Sci. Transl. Med.* 2021;13:eabj7790
- 11. Carsana L, Sonzogni A, Nasr A, Rossi RS, Pellegrinelli A, Zerbi P, Rech R, Colombo R,
  Antinori S, Corbellino M, Galli M, Catena E, Tosoni A, Gianatti A, Nebuloni M. Pulmonary
  post-mortem findings in a series of covid-19 cases from northern italy: A two-centre
  descriptive study. *Lancet Infect. Dis.* 2020;20:1135-1140
- Venkata C, Kashyap R, Farmer JC, Afessa B. Thrombocytopenia in adult patients with
  sepsis: Incidence, risk factors, and its association with clinical outcome. *J Intensive Care*.
  2013;1:9
- 527 13. Vandijck DM, Blot SI, De Waele JJ, Hoste EA, Vandewoude KH, Decruyenaere JM.
   528 Thrombocytopenia and outcome in critically ill patients with bloodstream infection. *Heart* 529 *Lung.* 2010;39:21-26
- 530 14. Wang T, Liu Z, Wang Z, Duan M, Li G, Wang S, Li W, Zhu Z, Wei Y, Christiani DC, Li A,
  531 Zhu X. Thrombocytopenia is associated with acute respiratory distress syndrome
  532 mortality: An international study. *PLoS One*. 2014;9:e94124
- ten Cate H, Schoenmakers SH, Franco R, Timmerman JJ, Groot AP, Spek CA, Reitsma
  PH. Microvascular coagulopathy and disseminated intravascular coagulation. *Crit. Care Med.* 2001;29:S95-97; discussion S97-98
- 536 16. Gando S, Levi M, Toh CH. Disseminated intravascular coagulation. *Nat Rev Dis Primers*.
  537 2016;2:16037

- 538 17. Levi M, Ten Cate H. Disseminated intravascular coagulation. *N. Engl. J. Med.*539 1999;341:586-592
- 540 18. Evans CE, Zhao YY. Impact of thrombosis on pulmonary endothelial injury and repair
  541 following sepsis. *Am J Physiol Lung Cell Mol Physiol.* 2017;312:L441-L451
- Levi M, Poll T. Coagulation in patients with severe sepsis. Semin. Thromb. Hemost.
  2015;41:9-15
- 544 20. Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ 545 dysfunction. *Thromb. Res.* 2012;129:290-295
- 546 21. Abadie Y, Bregeon F, Papazian L, Lange F, Chailley-Heu B, Thomas P, Duvaldestin P,
- 547 Adnot S, Maitre B, Delclaux C. Decreased vegf concentration in lung tissue and vascular 548 injury during ards. *Eur. Respir. J.* 2005;25:139-146
- 549 22. Bannerman DD, Goldblum SE. Mechanisms of bacterial lipopolysaccharide-induced
  550 endothelial apoptosis. *Am J Physiol Lung Cell Mol Physiol*. 2003;284:L899-914
- 551 23. Aird WC. The role of the endothelium in severe sepsis and multiple organ dysfunction 552 syndrome. *Blood*. 2003;101:3765-3777
- Evans CE, Iruela-Arispe ML, Zhao YY. Mechanisms of endothelial regeneration and
  vascular repair and their application to regenerative medicine. *Am J Pathol.* 2021;191:5265
- 556 25. Maniatis NA, Kotanidou A, Catravas JD, Orfanos SE. Endothelial pathomechanisms in 557 acute lung injury. *Vascul. Pharmacol.* 2008;49:119-133
- 558 26. Millar FR, Summers C, Griffiths MJ, Toshner MR, Proudfoot AG. The pulmonary 559 endothelium in acute respiratory distress syndrome: Insights and therapeutic 560 opportunities. *Thorax*. 2016;71:462-473
- 561 27. Gill SE, Rohan M, Mehta S. Role of pulmonary microvascular endothelial cell apoptosis in
  562 murine sepsis-induced lung injury in vivo. *Respir. Res.* 2015;16:109

- Haimovitz-Friedman A, Cordon-Cardo C, Bayoumy S, Garzotto M, McLoughlin M, Gallily
  R, Edwards CK, 3rd, Schuchman EH, Fuks Z, Kolesnick R. Lipopolysaccharide induces
  disseminated endothelial apoptosis requiring ceramide generation. *J Exp Med.*1997;186:1831-1841
- Zhao YY, Gao XP, Zhao YD, Mirza MK, Frey RS, Kalinichenko VV, Wang IC, Costa RH,
  Malik AB. Endothelial cell-restricted disruption of foxm1 impairs endothelial repair
  following lps-induced vascular injury. *J. Clin. Invest.* 2006;116:2333-2343
- 570 30. Fujita M, Kuwano K, Kunitake R, Hagimoto N, Miyazaki H, Kaneko Y, Kawasaki M,
  571 Maeyama T, Hara N. Endothelial cell apoptosis in lipopolysaccharide-induced lung injury
  572 in mice. *Int Arch Allergy Immunol.* 1998;117:202-208
- 573 31. Wiener-Kronish JP, Albertine KH, Matthay MA. Differential responses of the endothelial 574 and epithelial barriers of the lung in sheep to escherichia coli endotoxin. *J. Clin. Invest.*
- 575 1991;88:864-875
- de Souza PM, Lindsay MA. Apoptosis as a therapeutic target for the treatment of lung
  disease. *Curr. Opin. Pharmacol.* 2005;5:232-237
- 33. Huertas A, Montani D, Savale L, Pichon J, Tu L, Parent F, Guignabert C, Humbert M.
  Endothelial cell dysfunction: A major player in sars-cov-2 infection (covid-19)? *Eur. Respir.*J. 2020;56
- 34. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gardlund B,
  Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V,
  Janes J, Macias WL, Vangerow B, Williams MD, Group P-SS. Drotrecogin alfa (activated)
  in adults with septic shock. *N. Engl. J. Med.* 2012;366:2055-2064
- Vincent JL, Ramesh MK, Ernest D, LaRosa SP, Pachl J, Aikawa N, Hoste E, Levy H,
  Hirman J, Levi M, Daga M, Kutsogiannis DJ, Crowther M, Bernard GR, Devriendt J,
  Puigserver JV, Blanzaco DU, Esmon CT, Parrillo JE, Guzzi L, Henderson SJ, Pothirat C,
  Mehta P, Fareed J, Talwar D, Tsuruta K, Gorelick KJ, Osawa Y, Kaul I. A randomized,

double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of
recombinant human soluble thrombomodulin, art-123, in patients with sepsis and
suspected disseminated intravascular coagulation. *Crit. Care Med.* 2013;41:2069-2079
36. Bernard GR, Ely EW, Wright TJ, Fraiz J, Stasek JE, Jr., Russell JA, Mayers I, Rosenfeld
BA, Morris PE, Yan SB, Helterbrand JD. Safety and dose relationship of recombinant
human activated protein c for coagulopathy in severe sepsis. *Crit. Care Med.*2001;29:2051-2059

- 596 37. Dixon B, Smith RJ, Campbell DJ, Moran JL, Doig GS, Rechnitzer T, MacIsaac CM,
  597 Simpson N, van Haren FMP, Ghosh AN, Gupta S, Broadfield EJC, Crozier TME, French
  598 C, Santamaria JD. Nebulised heparin for patients with or at risk of acute respiratory
  599 distress syndrome: A multicentre, randomised, double-blind, placebo-controlled phase 3
  600 trial. *The Lancet. Respiratory medicine.* 2021;9:360-372
- 80. Evans CE, Humphries J, Mattock K, Waltham M, Wadoodi A, Saha P, Modarai B, Maxwell
  PH, Smith A. Hypoxia and upregulation of hypoxia-inducible factor 1alpha stimulate
  venous thrombus recanalization. *Arterioscler. Thromb. Vasc. Biol.* 2010;30:2443-2451
- Evans CE, Palazon A, Sim J, Tyrakis PA, Prodger A, Lu X, Chan S, Bendahl PO, Belting
  M, Von Euler L, Rundqvist H, Johnson RS, Branco C. Modelling pulmonary
  microthrombosis coupled to metastasis: Distinct effects of thrombogenesis on
  tumorigenesis. *Biology open*. 2017;6:688-697
- Huang X, Dai Z, Cai L, Sun K, Cho J, Albertine KH, Malik AB, Schraufnagel DE, Zhao YY.
  Endothelial p110gammapi3k mediates endothelial regeneration and vascular repair after
  inflammatory vascular injury. *Circulation*. 2016;133:1093-1103
- 41. Zhang X, Jin H, Huang X, Chaurasiya B, Dong D, Shanley TP, Zhao YY. Robust genome
  editing in adult vascular endothelium by nanoparticle delivery of crispr-cas9 plasmid DNA.
- 613 *Cell Rep.* 2022;38:110196

- Wuescher LM, Takashima A, Worth RG. A novel conditional platelet depletion mouse
  model reveals the importance of platelets in protection against staphylococcus aureus
  bacteremia. *J. Thromb. Haemost.* 2015;13:303-313
- 43. Neto-Neves EM, Brown MB, Zaretskaia MV, Rezania S, Goodwill AG, McCarthy BP,
- 618 Persohn SA, Territo PR, Kline JA. Chronic embolic pulmonary hypertension caused by
- 619 pulmonary embolism and vascular endothelial growth factor inhibition. *Am J Pathol.*
- 620 2017;187:700-712
- 44. Mulchrone A, Kellihan HB, Forouzan O, Hacker TA, Bates ML, Francois CJ, Chesler NC.
- A large animal model of right ventricular failure due to chronic thromboembolic pulmonary
- hypertension: A focus on function. *Front Cardiovasc Med*. 2018;5:189
- 45. Dixon B. The role of microvascular thrombosis in sepsis. *Anaesth. Intensive Care.*2004;32:619-629
- 46. Andersson CK, Claesson HE, Rydell-Törmänen K, Swedmark S, Hällgren A, Erjefält JS.
   Mice lacking 12/15-lipoxygenase have attenuated airway allergic inflammation and
- remodeling. *Am J Respir Cell Mol Biol*. 2008;39:648-656
- 47. Serhan CN, Jain A, Marleau S, Clish C, Kantarci A, Behbehani B, Colgan SP, Stahl GL,
- 630 Merched A, Petasis NA, Chan L, Van Dyke TE. Reduced inflammation and tissue damage
- in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory
   lipid mediators. *J Immunol.* 2003;171:6856-6865
- 48. Zarbock A, Distasi MR, Smith E, Sanders JM, Kronke G, Harry BL, von Vietinghoff S,
  Buscher K, Nadler JL, Ley K. Improved survival and reduced vascular permeability by
  eliminating or blocking 12/15-lipoxygenase in mouse models of acute lung injury (ali). *J Immunol.* 2009;183:4715-4722
- 49. Kühn H, Chan L. The role of 15-lipoxygenase in atherogenesis: Pro- and antiatherogenic
  actions. *Curr. Opin. Lipidol.* 1997;8:111-117

- 50. Evans CE, Bendahl PO, Belting M, Branco C, Johnson RS. Diverse roles of cell-specific
- 640 hypoxia-inducible factor 1 in cancer-associated hypercoagulation. *Blood*. 2016;127:1355-
- 641 1360
- 642

## 643 Acknowledgments

We are grateful to the Biorepository at the University of Illinois at Chicago for the sections of lung tissues from ARDS patients and to the Pulmonary Hypertension Breakthrough Initiatives (PHBI) for the lung sections from unused donor lungs. This work was supported in part by NIH grants R01HL123957, R01HL133951, R01HL148810, R01HL162299, and R01HL164014 to Y.Y.Z and by an AHA Career Development Award 19CDA34500000 to C.E.E.

649

## 650 Author Contributions

651 C.E.E. and Y.Y.Z. conceived and designed the experiments. C.E.E., X.Z., and N.M.

652 performed the experiments. C.E.E., X.Z., and D.W. analyzed the data. C.E.E., D.W., and Y.Y.Z.

interpreted the data. C.E.E. wrote the manuscript. Y.Y.Z. supervised the project and revised themanuscript.

655

## 656 Competing Interests

Y.Y. Zhao reported pending patent applications entitled "PLGA-PEG nanoparticles and
methods of uses", "Cationic polymer-formulated nanoparticles and methods of use". Y.Y. Zhao is
the founder and chief scientific officer of Mountview Therapeutics LLC. The authors have no
additional competing interests.

661

## 662 Data and Materials availability

663 All data are presented and included in the manuscript.

## 664 Figures Legends

Fig. 1. Opposite effects of mild versus severe lung thrombosis on LPS-induced ALI. (A) 665 666 Mice received either PBS vehicle (V) or indicated dose of MBs (i.v.) and 24hrs later received LPS (3mg/kg, i.p.). Lung tissues were collected for analyses at 36hrs post-LPS. EBA flux assay was 667 668 used to demonstrate that a dose of 1,000 MBs/mouse protected against LPS-induced pulmonary vascular permeability, but higher doses (e.g., 200,000 MBs/mouse) augmented LPS-induced 669 670 pulmonary vascular permeability. (B) MPO activity assay showing that 1,000 MBs/mouse protected against whereas 200,000 MBs/mouse augmented LPS-induced lung neutrophil 671 672 sequestration. (C-E) TUNEL staining and quantification of apoptosis (green). ECs were stained with anti-CD31 and anti-vWF antibodies (ECs, red). Nuclei were counterstained with DAPI (blue). 673 Arrows point to TUNEL<sup>+</sup> ECs. Scale bar = 10µm. (F-H) MSB staining and quantification of thrombi 674 and fibrin area. Arrows indicate fibrin thrombi. Scale bar = 100µm. \*P<0.05, \*\*P<0.01, \*\*\*P<0.001, 675 676 and \*\*\*\*P<0.0001; one-way ANOVA with Bonferroni post-tests (A-D, F, G).

677 Fig. 2. Mild lung thrombosis protects against LPS-induced ALI and improves survival. Mice received PBS (Veh) or 1,000 MBs/mouse (i.v.) and 24hrs later received LPS (3mg/kg, i.p.) or PBS 678 (Basal). Lung tissues were collected for analyses at 36hrs post-LPS. (A) EBA flux assay showing 679 680 that treatment with 1,000 MBs/mouse reduced lung vascular permeability in LPS-treated but not 681 basal mice. Values for 36hrs post-LPS are repeated in Fig 1A and 2A. (B) The effect of 1,000 682 MBs/mouse on basal and LPS-induced lung edema was measured by lung wet/dry weight ratio. Treatment with 1,000 MBs/mouse reduced lung edema in LPS-treated mice. (C-E) Histological 683 684 analysis of H&E-stained lung sections (E) showing that 1,000 MBs treatment reduced alveolar 685 edema (C), and alveolar septum thickening (D) in LPS-treated mice compared to MB-free (Veh) LPS-treated mice. In the representative images (E), arrows point to alveolar edema and 686 687 arrowheads indicate thickened septum. Scale bar =  $50\mu m$ . (**F**, **G**) The 1,000 MBs treatment given 688 after LPS challenge was also protective. At 2 or 8hrs after LPS (3mg/kg, i.p.), mice received PBS 689 (Veh) or 1.000 MBs (i,v.). At 36hrs post-LPS, lung tissues were collected for EBA flux assav (F) and MPO activity measurement (G). (H) Both pre- and post-LPS treatments with 1,000 690 691 MBs/mouse promoted survival. Mice received 1,000 MBs (i.v.) either 24hrs before (1k Pre-MBs) or 2hrs after (1k Post-MBs) a lethal dose of LPS (6mg/kg, i.p.). Survival was monitored for 1wk. 692 n = 12/group. \*P<0.05, \*\*P<0.01, and \*\*\*\*P<0.0001; one-way (**F**, **G**) or two-way ANOVA (**A-D**) 693 with Bonferroni post-tests; log-rank (Mantel-Cox) test (H). 694

## 695 Fig. 3. The effects of lung thrombosis on expression of survival factors in lungs of sepsischallenged mice. Mice received PBS (Veh) or indicated dose of MBs (i.v.) and 24hrs later were 696 697 challenged with LPS (3mg/kg, i.p.). At 24hrs post-LPS, lung tissues were collected for RNA 698 sequencing and gRT-PCR analyses. (A) Expression heatmap of survival genes that were 699 identified by RNA sequencing of whole lung samples to be downregulated in vehicle-treated LPS mouse lungs versus basal mice and restored in LPS mice receiving 1,000 but not 200,000 MBs. 700 701 (B) QRT-PCR analysis confirming the effect of varying extents of lung thrombosis on the 702 expression patterns of survival genes in whole lungs of basal compared with sepsis-challenged 703 mice. (C, D) QRT-PCR analysis of expression of the survival factors in isolated pulmonary cells 704 from LPS-challenged mice, identifying gene induction by 1,000 MBs (MBs) in non-ECs (CD31 705 cells) (**C**) and/or ECs (CD31<sup>+</sup> cells) (**D**). Alox15 and Cd22 were the 2 genes that were upregulated 706 only in ECs. \*P<0.05, \*\*P<0.01, and \*\*\*\*P<0.001; one-way ANOVA with Bonferroni post-test (B) 707 or independent t-tests (C, D).

## 708 Fig. 4. Mild lung thrombosis protects against LPS-induced ALI via endothelial Alox15. (A)

709 Diagrammatical representation of the experimental procedure. Adult mice received a mixture of nanoparticle:CRISPR<sup>CDH5</sup> plasmid DNA expressing Cas9 under control of the human CDH5 710 promoter and gene-specific (Alox15 or Cd22) guide RNA (designated as  $Alox^{\Delta EC}$  or Cd22<sup> $\Delta EC$ </sup>. 711 respectively) or scrambled guide RNA (WT) driven by the U6 promoter (40ug plasmid 712 DNA/mouse, i.v.). At 7days later, mice received PBS (Veh) or 1,000 MBs (i.v.) followed by LPS 713 714 challenge (3mg/kg, i.p.) at 24hrs later. Lung tissues were collected at 36hrs post-LPS for various 715 analyses. (B) ELISA analysis demonstrating diminished Alox15 expression in lung ECs but not in non-ECs isolated from CRISPR/Alox15 gRNA-plasmid-administered basal mice. Lung tissues 716 717 were collected from mice at 7 days post-nanoparticle delivery of plasmid DNA. (C) CRISPR 718 plasmid DNA-mediated disruption of endothelial Alox15 but not endothelial Cd22 reversed the decrease in pulmonary vascular permeability caused by treatment with 1,000 MBs/mouse. (D) 719 Knockdown of endothelial Alox15 but not Cd22 also reversed the 1,000 MBs treatment-elicited 720 721 decrease in MPO activity. (E, F) Quantitative analyses of H&E-stained lung sections showing reversal of 1,000 MB treatment-induced decreases in alveolar edema (E), and septum thickening 722 (F) in *Alox<sup>dEC</sup>* mice. (G-I) Quantifications of pulmonary EC apoptosis (G) and total apoptosis (H) 723 724 in LPS-challenged mice. Lung cryosections were stained with FITC-TUNEL (apoptosis, green) 725 and anti-CD31/-vWF antibodies (ECs, red). Nuclei were counterstained with DAPI (blue). Arrows point to TUNEL<sup>+</sup> ECs (I). Scale bar = 10µm. \*P<0.05, \*\*P<0.01, \*\*\*P<0.001, and \*\*\*\*P<0.0001; 726 727 two-way (B) or one-way ANOVA with Bonferroni post-tests (C-H).

728 Fig. 5. Overexpression of endothelial Alox15 inhibits the detrimental effects of severe lung 729 thrombosis on sepsis-induced lung injury. (A) Diagrammatical representation of the experimental procedure. (B) ELISA analysis demonstrating a marked increase of Alox15 730 731 expression in isolated lung ECs but not non-ECs of Alox15 plasmid (Alox15)-transduced mice 732 compared to empty vector (V) mice. Human CDH5 promoter was employed in the plasmid DNA. 733 (C) EBA flux assay demonstrating endothelial Alox15 overexpression reversed the 200,000 MBselicited increase of pulmonary vascular permeability in LPS mice. (D, E) Quantification of H&E-734 735 stained mouse lung sections showing that overexpression of endothelial Alox15 inhibited the 736 severe thrombosis-induced increases in alveolar edema (D) and septum thickening (E). (F-H) Quantifications of apoptosis in the lung demonstrating that 200,000 MBs/mouse-induced 737 increases in EC apoptosis (F) and total apoptosis (G) was inhibited by EC-specific Alox15 738 739 overexpression. Lung cryosections were stained with FITC-TUNEL (green) and with anti-CD31 740 and -vWF antibodies (ECs, red), Nuclei were counterstained with DAPI (blue). In the representative micrographs (F), arrows point to TUNEL<sup>+</sup> ECs. Scale bar =  $10\mu m$ . \*P<0.05, 741 \*\*P<0.01, and \*\*\*\*P<0.0001; one-way ANOVA with Bonferroni post-tests (B-G). 742

743 Fig. 6. Restoration of mild pulmonary thrombosis inhibits thrombocytopenia-enhanced 744 inflammatory lung injury in sepsis-challenged mice. (A) Diagrammatical representation of the experimental procedure. DTR<sup>Pf4Cre</sup> (PF4) mice or DTR<sup>Pf4-</sup> (WT) mice received DT (20ng/g/day, 745 746 i.p.) then PBS (Veh) or indicated dose of MBs (i.v.) followed by LPS (3mg/kg, i.p.). (B) 747 Representative images of MSB-stained lung cross-sections, showing apparent restoration of 748 thrombosis in thrombocytopenia PF4 mice by 2,000 MB treatment. Arrows indicate fibrin thrombi. 749 Scale bar =  $100\mu m$ . (C) Quantifications of thrombi number revealing that thrombocytopenia 750 resulted in reduced pulmonary thrombosis in sepsis-challenged mice, which was reversible by 751 MB treatment. (D) Representative images of H&E lung cross-sections. Arrows indicate alveolar edema. Arrowheads point to septal thickening. Scale bar = 50µm. (E, F) Quantifications of alveolar 752 753 edema and septal thickening. (G) EBA flux assay demonstrating that thrombocytopenia-induced 754 increase of pulmonary vascular permeability in PF4 mice was inhibited by treatment with low 755 doses (1,000-5,000) of MBs/mouse. (H) MPO activity assay. (I) Thrombocytopenia-induced increase of pulmonary vascular permeability in PF4 LPS mice was reversed by post-sepsis 756 757 restoration of lung thrombosis. 2,000 MBs or PBS (Veh) were given at 2hrs after LPS. (J) MPO 758 activity. (K) Treatment with 2,000 MBs improved survival in thrombocytopenic LPS-challenged 759 mice. At 48hrs after final DT injection, mice received 4mg/kg LPS (i.p.). At 24hrs before (Pre-MBs) 760 or 2hrs after (Post-MBs) LPS challenge, mice received PBS (Veh) or 2,000 MBs. n = 8-9/group. 761 \*P<0.05, \*\*P<0.01, \*\*\*P<0.001, and \*\*\*\*P<0.001; one-way ANOVA with Bonferroni post-test (**C**, 762 E-J); log-rank (Mantel-Cox) test (K).

## 763 Fig. 7. Mild lung thrombosis protects against CLP-induced ALI via endothelial Alox15. (A)

Mice received either PBS vehicle (V) or indicated dose of MBs (i.v.) and 24hrs later received CLP. 764 Lung tissues were collected for analyses at 36hrs post-CLP. EBA flux assay was used to 765 766 demonstrate that a dose of 1,000 MBs/mouse protected against CLP-induced pulmonary vascular 767 permeability, but the high dose (i.e., 200,000 MBs/mouse) augmented CLP-induced pulmonary 768 vascular permeability. (B) MPO activity assay showing that 1,000 MBs/mouse protected against whereas 200,000 MBs/mouse augmented CLP-induced lung neutrophil sequestration. (C-I) Adult 769 mice received a mixture of nanoparticle:CRISPR<sup>CDH5</sup> plasmid DNA expressing Cas9 under control 770 of the human CDH5 promoter and gene-specific (Alox15) guide RNA (designated as  $\Delta EC$ ) or 771 772 scrambled guide RNA (WT) driven by the U6 promoter. At 7 days later, mice received PBS vehicle 773 (V) or 1,000 MBs (i.v.) followed by CLP challenge at 24hrs later. Lung tissues were collected at 36hrs post-CLP for various analyses. CRISPR plasmid DNA-mediated disruption of endothelial 774 775 Alox15 reversed the decrease in pulmonary vascular permeability caused by treatment with 1,000 776 MBs/mouse (C). Knockdown of endothelial Alox15 also reversed the 1,000 MBs treatment-elicited 777 decrease in MPO activity (D). TUNEL staining and quantification of apoptosis (green) (E, F). ECs 778 were stained with anti-CD31 and anti-vWF antibodies (ECs, red). Nuclei were counterstained with DAPI (blue). Arrows point to TUNEL<sup>+</sup> ECs. Scale bar = 10µm. Quantitative analyses of H&E-779 780 stained lung sections showing reversal of 1,000 MB treatment-induced decreases in alveolar edema (G) and septum thickening (H) in  $Alox^{AEC}$  mice. In the representative images (I), arrows 781 782 point to alveolar edema and arrowheads indicate thickened septum. Scale bar = 50µm. \*P<0.05, 783 \*\*P<0.01, \*\*\*P<0.001, and \*\*\*\*P<0.0001; one-way ANOVA with Bonferroni post-tests (**A-D, F, G**).

## 784 Fig. 8. ALOX15<sup>+</sup> ECs were markedly reduced in lungs of non-survival ARDS patients. (A) 785 Representative images of in situ RNA hybridization (RNAscope) assays for ALOX15 expression (green) in archived postmortem lung paraffin sections from ARDS patients and unused donor 786 787 controls. ECs were immunostained with anti-CD31 and -vWF antibodies (red). Nuclei were 788 counterstained with DAPI (blue). Arrows indicate $ALOX15^+$ lung ECs. Scale bar = 10µm. (B) 789 Quantification of $ALOX15^+$ ECs in lung sections showing reduced $ALOX15^+$ ECs in lung sections from ARDS patients compared with normal controls. \*P<0.05; unpaired t-test. (C) Diagrammatical 790 791 summary of key findings. Mild lung thrombosis reduces sepsis-induced inflammatory lung injury, 792 whereas severe or impaired lung thrombosis induced by thrombocytopenia augments sepsis-793 induced inflammatory lung injury. Restoration of lung thrombosis in platelet-depleted mice inhibits 794 the thrombocytopenia-induced increase in lung injury and promotes survival. The protective 795 effects elicited by mild lung thrombosis are mediated by inhibiting the sepsis-induced 796 downregulation of endothelial Alox15, which promotes EC survival.

medRxiv preprint doi: https://doi.org/10.1101/2023.03.29.23287934; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.





**TUNEL CD31/vWF DAPI** 

Vehicle

Н

1k MBs

200k MBs



**Erythrocytes Fibrin Collagen** 

medRxiv preprint doi: https://doi.org/10.1101/2023.03.29.23287934; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.







Figure 4





Figure 6

medRxiv preprint doi: https://doi.org/10.1101/2023.03.29.23287934; this version posted March 31, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



mdRxiv preprint doi: https://doi.org/10.1101/2023.03.29.23287934; this version posted March 31.2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CD31/vWF ALOX15 DAPI Merge CD31/vWF ALOX15 DAPI Merge ALOX15 DAPI MERGE



Normal

ARDS

